GCM
IRWD icon

Gladius Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Gladius Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,072
Closed -$32.3K – 417
2023
Q1 		$32.3K Sell
3,072
-104
-3% -$1.17K ﹤0.01% 276
2022
Q4 		$39.4K Buy
+3,176
New +$36K ﹤0.01% 227
2022
Q3 		– Sell
-4,761
Closed -$55K – 438
2022
Q2 		$55K Buy
+4,761
New +$56.1K ﹤0.01% 245

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Gladius Capital Management's IRWD Position: Q2 2023 in Review

Gladius Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2023, closing a stake of 3,072 shares — an estimated $32.3K sold.

Gladius Capital Management first reported a position in IRWD in Q2 2022 and held it in 3 quarters. The position peaked at $55K in Q2 2022. 252 funds tracked by Wall St. Rank hold IRWD as of Q2 2023.

  • Gladius Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Gladius Capital Management sold 3,072 Ironwood Pharmaceuticals shares in Q2 2023, an estimated $32.3K.
  • Gladius Capital Management first reported a position in Ironwood Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Gladius Capital Management's Ironwood Pharmaceuticals position peaked at $55K in Q2 2022.
  • 252 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2023.

Based on Gladius Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.